link rel="shortcut icon" type="image/x-icon" href="medrx-education.com/files/theme/favicon.ico"
The first fully implantable neurostimulator for the treatment of OSA has been approved by the US Food and Drug Administration (FDA). The Inspire Upper Airway Stimulation device was approved for the second-line treatment of patients suffering from moderate to severe OSA who cannot undergo continuous positive airway pressure therapy. During inspiration, while the patient is sleeping, the implant stimulates the hypoglossal nerve, causing the upper airway muscles to contract and pull the base of the tongue forward.
Obstructive sleep apnea (OSA) is a sleep disorder that involves cessation or significant decrease in airflow in the presence of breathing effort. It is the most common type of sleep-disordered breathing and is characterized by recurrent episodes of upper airway collapse during sleep. These episodes are associated with recurrent oxyhemoglobin desaturations and arousals from sleep.
OSA that is associated with excessive daytime sleepiness is commonly called obstructive sleep apnea syndrome—also referred to as obstructive sleep apnea-hypopnea syndrome.
Conservative Management (For Mild OSA):
Mechanical measures (for moderate-severe OSA):
By: Ralph Downey III, PhD; Chief Editor: Zab Mosenifar, MD
Read Detailed Article at: http://emedicine.medscape.com/article/295807-overview?src=wnl_ref_prac_imed&uac=192123MZ